Alzheimer's Disease and Microglia: A Survey on Lipid Droplet Accumulation, Neuroinflammation, and Neurodegeneration

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder predominantly affecting the elderly, characterized by cognitive decline and memory loss. This survey paper explores the complex interplay between microglial dysfunction, lipid droplet accumulation, neuroinflammation, and impaired brain metabolism in AD pathogenesis. Microglia, the brain's resident immune cells, are crucial for maintaining homeostasis and modulating neuroinflammatory responses. However, their dysregulation in AD exacerbates neuroinflammation, contributing to the accumulation of amyloid-beta plaques and neurofibrillary tangles—hallmark features of AD. The accumulation of lipid droplets within microglia, indicative of altered lipid metabolism, further intensifies neuroinflammatory responses and exacerbates neurodegeneration. Recent research highlights the gut-brain axis's role in modulating neuroinflammation and its potential link to AD progression, suggesting novel therapeutic avenues. Advances in neuroimaging and machine learning techniques have improved early diagnosis and disease trajectory predictions, facilitating the development of targeted interventions. The survey underscores the significance of integrating genetic, imaging, and clinical data to enhance our understanding of the intricate relationships between lipid metabolism, neuroinflammation, and neurodegeneration. Future research should focus on refining computational models and exploring lifestyle interventions like intermittent fasting, which show promise in modulating neuroprotection and synaptic plasticity. By bridging existing knowledge gaps, this comprehensive exploration of interconnected processes in AD aims to inform clinical and research paradigms, ultimately transforming our understanding and treatment of neurodegenerative disorders.

1 Introduction

1.1 Overview of Alzheimer's Disease

Alzheimer's Disease (AD) is a major global health concern, primarily affecting the elderly and characterized by progressive cognitive decline and memory loss. As the most common form of dementia, AD poses a significant burden on healthcare systems worldwide, with increasing incidence rates in both developed and developing nations [1]. The disease's multifactorial nature, encompassing various biological pathways, necessitates a thorough understanding of its shared causal mechanisms to develop effective therapeutic strategies [2].

The pathophysiology of AD is marked by the accumulation of amyloid-beta plaques and neurofibrillary tangles, which are crucial in the transition from asymptomatic stages to advanced cognitive impairment [3]. Advances in genetic and molecular research have led to the identification of potential biomarkers and treatment targets [4]. Moreover, disruptions in brain functional connectivity are correlated with cognitive deficits, highlighting the need for integrated approaches to address these complex challenges [5].



Figure 1: chapter structure

Emerging evidence underscores the involvement of the gut-brain axis in AD pathogenesis, presenting new therapeutic avenues [6]. Early detection and intervention are crucial for halting disease progression, necessitating advanced diagnostic modalities like MRI and genomic analyses to identify predictive biomarkers. Addressing the complexities of Alzheimer's Disease is vital for mitigating its public health impact and improving patient care outcomes.

1.2 Significance of Microglia and Lipid Droplets

Microglia, the resident immune cells of the central nervous system, play a critical role in maintaining brain homeostasis and modulating neuroinflammatory responses, significantly influencing the pathogenesis of Alzheimer's Disease (AD). While microglia are essential for brain development and function under normal conditions, their dysregulation can exacerbate neurodegenerative processes. In AD, microglial dysfunction is linked to increased neuroinflammation and the accumulation of amyloid-beta plaques and neurofibrillary tangles, which are hallmark features of the disease. Environmental factors, including systemic infections and endotoxins, can influence microglial activation, potentially exacerbating neuroinflammation and enhancing amyloid-beta and tau pathology associated with AD. Furthermore, early-life immune challenges, such as maternal infections and stress, have been associated with long-term alterations in microglial function, implicating environmental factors in AD's neurodegenerative processes [7, 8, 9, 10, 11].

Lipid droplets in microglia have emerged as significant contributors to AD pathology, with their accumulation linked to altered lipid metabolism and increased neuroinflammatory responses that impact microglial function and contribute to neurodegeneration. The presence of lipid droplet-accumulating microglia (LDAM) in aging brains highlights their dysfunctional and pro-inflammatory state, potentially exacerbating neurodegenerative diseases [12]. Understanding how lipid droplets influence microglial activity and the broader neuroinflammatory environment is crucial for identifying novel therapeutic targets.

AI-generated, for reference only.

Recent studies suggest that impaired formation of plasma membrane lipid rafts, essential for synaptic function and memory processes, may contribute to sporadic AD, emphasizing cholesterol's role in these dynamics [13]. By elucidating the interactions between microglia, lipid droplets, and inflammatory mediators, this survey aims to enhance our understanding of AD and facilitate the development of innovative treatment strategies.

1.3 Interconnected Processes in AD

Alzheimer's Disease (AD) is characterized by a complex interplay of pathological processes that contribute to its progression. Central to these processes are lipid droplet accumulation, neuroinflammation, and microglial dysfunction, which are intricately linked in AD's pathogenesis [12]. Lipid droplets within microglia are not merely metabolic by-products but indicative of altered lipid homeostasis and heightened inflammatory responses that exacerbate neurodegeneration [12]. This interconnectedness is further complicated by the dual role of toll-like receptors (TLRs) in mediating neuroinflammation, which can exert both protective and detrimental effects on neuronal health through their regulation of microglial activity [14].

Historically, research methodologies have often examined these components in isolation, which fails to capture the dynamic and interrelated nature of these processes in AD [15]. Recent advances in neuroimaging techniques have improved the classification and prediction of mild cognitive impairment (MCI) and AD, providing insights into the morphological changes associated with aging and disease progression. These imaging modalities underscore the importance of considering the cumulative impact of lipid droplet accumulation and neuroinflammation on brain structure and function.

By investigating the synergistic effects of neurodegenerative processes, researchers can gain deeper insights into the complex mechanisms contributing to AD, characterized by -amyloid plaque accumulation and tau protein tangles. This understanding can facilitate the development of more targeted therapeutic interventions that address the interconnected pathways involved in neurodegeneration, including promising non-pharmacological approaches such as neurofeedback therapy and ultrasound ablation of amyloid plaques, which have shown potential in improving cognitive function and alleviating psychiatric symptoms associated with mild cognitive impairment and dementia [16, 17, 18, 19, 20].

1.4 Importance of the Survey

This survey enhances the understanding of Alzheimer's Disease (AD) by examining the intricate interactions among microglia, lipid droplets, neuroinflammation, and neurodegeneration. It aims to conduct a meta-analysis of RNA-Seq studies on neurodegenerative diseases, focusing on common gene expression patterns and pathways [21]. The multifaceted nature of AD necessitates a comprehensive exploration to elucidate its pathophysiology, diagnosis, and treatment, particularly given the challenges in early detection due to costly and invasive diagnostic methods [22].

Recent advancements in machine learning and deep learning techniques have significantly improved the classification of Alzheimer's disease using MRI data, despite challenges posed by limited datasets. These technologies facilitate early diagnosis, which is crucial since brain structural alterations are often advanced by the time diagnosis occurs [23]. Furthermore, the survey explores the potential of non-invasive early diagnostic methods, such as photobiomodulation (PBM), which present promising avenues for translating research from bench to bedside [24].

By integrating findings across diverse research domains, the survey provides a holistic perspective that informs both clinical and research paradigms. It highlights the potential of innovative approaches, such as Disease2Vec, to predict individual patient status within the continuous progression of Alzheimer's Disease [3]. This comprehensive approach seeks to bridge existing knowledge gaps and foster the development of novel therapeutic strategies for Alzheimer's Disease, ultimately transforming our understanding of neurodegenerative disorders and improving patient outcomes.

1.5 Structure of the Survey

The survey is meticulously structured to provide a comprehensive examination of Alzheimer's Disease (AD), focusing on key components such as microglia, lipid droplet accumulation, neuroinflammation, and neurodegeneration. It begins with an introduction that outlines the significance of these elements

in the context of AD, followed by a detailed background section that delves into the prevalence, symptoms, and pathophysiology of the disease. This section introduces pivotal concepts such as amyloid-beta plaques, tau protein tangles, and the role of microglia, alongside an exploration of lipid droplets and neuroinflammation within the broader scope of brain metabolism and neurodegeneration.

Subsequent sections dissect the role of microglia in AD, examining their function in maintaining brain homeostasis and their dysregulation's contribution to disease progression. The survey transitions into an in-depth analysis of lipid droplet accumulation in microglia, exploring mechanisms of formation and alterations in lipid metabolism. This is followed by a discussion on neuroinflammation, highlighting the contributions of microglial and other cellular factors to this process and its exacerbation of neurodegeneration.

The survey conducts an in-depth examination of impaired brain metabolism in Alzheimer's disease (AD), emphasizing the critical roles of glucose and lipid metabolism in exacerbating cognitive decline. It investigates the underlying mechanisms connecting lipid droplets to metabolic dysfunction, highlighting their significance as dynamic organelles involved in cellular signaling and metabolic regulation within the central nervous system, particularly in neurodegenerative contexts [25, 26, 4, 27, 13]. An analysis of the interplay between lipid droplet accumulation, neuroinflammation, and neurodegeneration is provided, emphasizing recent research findings and models used to study these interactions.

The structure also incorporates stages such as clinical evaluation, current pharmacological treatments, and future research directions, targeting the underlying pathologies of AD [17]. Additionally, the survey organizes the research into stages including data preprocessing, model training, and evaluation metrics, using criteria like applicability and effectiveness [28].

The conclusion integrates the principal findings from the analysis of clinical and biological characteristics associated with Alzheimer's Disease (AD), emphasizes the implications of the identified interconnected processes for understanding AD progression, and identifies promising avenues for future research, including the exploration of the role of Pregnancy-Associated Protein-A (PAPP-A) and the application of machine learning methods to enhance diagnostic accuracy and therapeutic strategies [29, 16]. This structured approach ensures a thorough exploration of AD, integrating diverse research domains to bridge knowledge gaps and inform both clinical and research paradigms.The following sections are organized as shown in Figure 1.

2 Background

2.1 Prevalence and Symptoms of Alzheimer's Disease

Alzheimer's Disease (AD) poses a significant global health challenge, with its prevalence rising sharply due to an aging population. The economic impact of AD is substantial, costing approximately $1trillionannually, highlightingitsburdenonhealthcaresystemsworldwide$[20]$.Ageisthe foremostriskfactor, butgend consuming, limitingwidespreadscreening.Advancesinpredictivemodeling, suchasrandomforestalgorithmsandneu$

AD is marked by progressive cognitive decline, memory impairment, and behavioral changes, symptomatic of underlying neurodegenerative processes exacerbated by aging [32]. Addressing AD's prevalence and symptoms through improved diagnostic and management strategies is essential to mitigate its profound impact on individuals and society.

2.2 Pathophysiology of Alzheimer's Disease

AD is a complex neurodegenerative disorder defined by amyloid-beta (A) plaques and neurofibrillary tangles composed of hyperphosphorylated tau proteins, central to its pathophysiology and progression [33]. A plaques result from abnormal proteolytic processing of amyloid precursor protein (APP), disrupting neuronal communication and synaptic function [33]. Simultaneously, neurofibrillary tangles, primarily formed by hyperphosphorylated tau proteins, lead to microtubule disintegration, exacerbating neuronal dysfunction and cell death [33]. The pathological interplay between A and tau proteins drives neurodegeneration, as their aggregation and spread are linked to disease progression [33].

Beyond these hallmark features, shared biological mechanisms with conditions like type 2 diabetes mellitus necessitate an integrated approach to understanding these interconnected diseases. The

gut-brain axis, for example, suggests a link between gut function and AD-related cognitive decline, highlighting a bidirectional communication axis between gut and brain [6]. Furthermore, brain heterogeneity among AD patients complicates the identification of distinct disease subtypes and progression patterns, requiring advanced methodologies to unravel these complexities [34].

Advancements in neuroimaging techniques, such as deep neural network heatmaps, improve differentiation between AD patients and healthy controls [35]. Identifying combinatorial biomarkers for AD is crucial for enhancing diagnostic accuracy and developing targeted therapeutic strategies [1]. A comprehensive understanding of AD's pathophysiology, including shared mechanisms with other diseases, is essential for advancing knowledge and developing effective interventions.

2.3 Introduction to Lipid Droplets and Neuroinflammation

Central to AD pathogenesis are amyloid-beta (A) plaques and neurofibrillary tangles [33]. Among the multifaceted processes implicated in AD, lipid droplets and neuroinflammation have emerged as significant contributors. Lipid droplets in microglia indicate disrupted lipid homeostasis, a hallmark of neurodegeneration, linked to impaired lipid raft formation essential for synaptic function and neural communication [13]. Neuroinflammation, characterized by microglial activation and pro-inflammatory cytokine release, initially serves a protective role but can lead to neuronal damage when chronic [33].

The interplay between lipid droplets and neuroinflammation is pivotal in AD pathogenesis. Lipid droplet-accumulating microglia (LDAM) in aging brains indicate a dysfunctional, pro-inflammatory state, exacerbating neurodegenerative processes [12]. Existing models have been criticized for inadequately capturing the complex dynamics of protein aggregation and the roles of lipid droplets and neuroinflammation, underscoring the need for novel therapeutic targets [36].

Integrating genetic, imaging, and clinical data with advances in spatio-temporal modeling and deep learning architectures can transform our understanding of AD and improve patient outcomes. Techniques like X-ray phase contrast tomography (XPCT) offer insights into the gut's microenvironment, elucidating complex interactions in AD pathogenesis [13]. The study of lipid droplets and neuroinflammation in AD is crucial for advancing therapeutic strategies and mitigating disease progression.

2.4 Brain Metabolism and Neurodegeneration

Disruptions in brain metabolism are critically linked to Alzheimer's Disease (AD) and play a significant role in its progression. Multimodal imaging techniques, such as diffusion-weighted imaging (DWI), functional magnetic resonance imaging (fMRI), and magnetoencephalography (MEG), have revealed disrupted core-periphery structures in AD brain networks compared to healthy controls, highlighting altered metabolic activity and connectivity that contribute to cognitive decline and neuronal loss [37].

Despite the absence of predictive models for metabolic disruptions in AD, advancements like the Data-driven Inference of Vertex-wise Evolution (DIVE) model offer promising avenues for reconstructing long-term brain pathology patterns from short-term longitudinal data [38]. These models utilize vertex-wise biomarker measurements to provide insights into the spatial and temporal progression of metabolic disruptions in AD.

The interplay between brain metabolism and neurodegeneration is crucial for understanding AD, as maintaining metabolic homeostasis is essential for optimal brain function [39]. Blood-based metabolic signatures, including metabolites related to amino acids and oxidative stress, have been identified as potential biomarkers for AD pathogenesis [25]. Lifestyle interventions like intermittent fasting, caloric restriction, and caloric restriction mimetics may offer neuroprotection, influence synaptic plasticity, and promote neurogenesis, particularly in the context of aging and neurodegenerative diseases such as AD [40]. Understanding the relationship between brain metabolism and neurodegeneration in AD is crucial for developing effective therapeutic strategies to mitigate disease progression.

In examining the multifaceted roles of microglia in Alzheimer's Disease (AD), it is essential to consider their hierarchical structure, which encompasses various functions including homeostasis, dysregulation, and neuroinflammation. As illustrated in Figure 2, this figure succinctly captures the complexity of microglial roles within the context of AD. It not only emphasizes the technological

advancements that have enhanced our understanding of these cells but also outlines the therapeutic implications arising from this knowledge. Furthermore, the figure addresses the challenges and factors that influence microglial activity, thereby providing a comprehensive overview that enriches our discussion of their involvement in the pathophysiology of Alzheimer's Disease.



Figure 2: This figure illustrates the hierarchical structure of microglial roles in Alzheimer's Disease, including their function and homeostasis, dysregulation, and involvement in neuroinflammation. It highlights technological advancements and therapeutic implications, as well as challenges and factors influencing microglial activity in the context of AD.

3 Role of Microglia in Alzheimer's Disease

3.1 Microglial Function and Homeostasis

Microglia, the central nervous system's primary immune cells, are crucial for brain homeostasis, performing synaptic pruning, modulating neuroinflammatory responses, and phagocytosing apoptotic cells and debris, thereby maintaining neural tissue integrity [41]. In Alzheimer's Disease (AD), microglia are vital for clearing amyloid-beta (A) plaques, which impair neuronal communication and synaptic function due to toxic aggregation from aberrant amyloid precursor protein (APP) processing [33]. Despite their essential role, microglial dysregulation in AD results in chronic neuroinflammation, exacerbating neurodegeneration.

Advancements in neuroimaging, particularly multimodal MRI and machine learning, have deepened our understanding of microglial roles in AD. These technologies have revealed structural and functional brain changes related to AD, highlighting alterations in sensory-motor and visual resting state networks, and genetic factors involved in endocytosis and amyloid-beta metabolism. Deep learning frameworks have achieved high diagnostic accuracy in distinguishing AD patients from healthy controls and predicting progression from mild cognitive impairment (MCI) to AD [42, 43, 44, 29]. Additionally, tools like 3D spatio-temporal modeling and deep learning architectures, such as 3D multigrid neural networks (3D-MgNet), further elucidate the disease's impact on brain structure and function. Non-invasive imaging methods, including Raman spectroscopy, offer chemically specific insights into molecular changes associated with AD.

Regulating microglial activity is crucial to prevent excessive neuroinflammation, which can worsen neurodegeneration [33]. Understanding microglial function balance is essential for developing targeted therapies aimed at preserving cognitive function and mitigating AD progression. Emerging research on caloric restriction and similar interventions shows potential in modulating neuroinflammation and promoting synaptic plasticity, warranting further exploration [40]. Leveraging these insights could lead to effective therapies that preserve cognitive function and slow AD progression [4].

AI-generated, for reference only.

3.2 Dysregulation of Microglia in Alzheimer's Disease

Microglial dysregulation is pivotal in Alzheimer's Disease (AD) pathogenesis. Normally, microglia maintain neural homeostasis by regulating brain development, synaptic pruning, and clearing apoptotic cells and debris, ensuring a healthy CNS environment [41, 7]. In AD, however, microglial dysfunction exacerbates neuroinflammatory processes, contributing to neurodegeneration.

This dysregulation correlates with pathological amyloid-beta (A) plaques and neurofibrillary tangles, primarily composed of hyperphosphorylated tau proteins [33]. The interaction between A and tau is central to AD's pathophysiology, as their aggregation disrupts neuronal communication and promotes further damage, exacerbated by the prion-like propagation of tau pathology [45].

Recent studies suggest a connection between microglial dysregulation in AD and shared pathways with type 2 diabetes, indicating broader systemic involvement in disease progression [2]. This underscores the need for comprehensive approaches to understand AD's multifaceted nature and its association with metabolic disorders.

Microglial dysregulation complexity is compounded by the non-periodicity of cellular structures, challenging effective modeling of protein aggregation and clearance dynamics in vivo [36]. Despite advances in machine learning and neuroimaging, predicting individual disease trajectories across clinical stages remains difficult, emphasizing the need for large datasets to improve model accuracy and avoid overfitting.

Addressing microglial dysregulation is imperative for developing effective therapeutic strategies targeting underlying pathological processes. Utilizing advanced methodologies, such as X-ray phase contrast tomography, researchers investigate relationships among microglial activity, lipid droplet accumulation, and neurodegeneration in AD. This approach aims to elucidate how alterations in gut structure and function correlate with amyloid-beta presence in the brain, contributing to a deeper understanding of AD pathogenesis and guiding early diagnostic and therapeutic strategies [44, 46, 16, 6, 27].

As illustrated in Figure 3, the role of microglial dysregulation in Alzheimer's Disease is highlighted through key microglial functions, pathological features, and research approaches. Understanding these interactions is crucial for advancing therapeutic strategies and improving patient outcomes.



Figure 3: This figure illustrates the role of microglial dysregulation in Alzheimer's Disease, highlighting key microglial functions, pathological features, and research approaches.

3.3 Role of Microglia in Neuroinflammation

Microglia are central to regulating neuroinflammation in Alzheimer's Disease (AD). Under normal conditions, they maintain neuronal homeostasis through synaptic pruning and responses to injury or infection [41]. In AD, however, microglia become chronically activated, producing pro-inflammatory cytokines and mediators that exacerbate neuronal injury and contribute to neurodegeneration.

The dual nature of microglial activation complicates therapeutic strategies, as these cells can have both neuroprotective and neurotoxic effects depending on the context [41]. In early AD stages, microglia may aid in clearing A plaques through phagocytosis, potentially mitigating neurotoxic effects [33]. However, as AD progresses, chronic microglial activation leads to sustained inflammatory responses that promote additional neuronal damage.

Recent studies elucidate microglia's contribution to neuroinflammation in AD, highlighting toll-like receptors (TLRs) role in modulating microglial activity and their capacity to mediate protective and harmful effects on neurons [14]. Interactions between microglia and factors like A and tau proteins underscore the complexity of neuroinflammatory processes in AD [19].

Systemic factors, such as peripheral infections, further complicate microglial roles by exacerbating the inflammatory response and cognitive decline in AD [10]. Understanding the context-dependent functions of microglia is essential for developing targeted therapeutic strategies to modulate their activity and mitigate chronic neuroinflammation's detrimental effects [41].

Advancements in computational models and imaging techniques provide new insights into microglial roles in AD. For instance, label-free Raman micro-spectroscopy, combined with quantitative hyperspectral image analysis, offers novel perspectives on molecular interactions within the brain [47]. Hierarchical structures capturing anatomical variations in brain MRI scans have improved AD classification, enhancing understanding of microglial dynamics and their role in disease progression [48].

4 Lipid Droplet Accumulation in Microglia

The intricate role of lipid metabolism in neurodegenerative diseases, notably Alzheimer's Disease (AD), underscores its significance in disease pathophysiology. Microglia, the brain's resident immune cells, exhibit notable lipid droplet (LD) accumulation, indicative of disrupted metabolic processes and inflammatory responses. This section delves into the mechanisms governing lipid droplet formation in microglia, examining enzymatic pathways and regulatory factors, alongside the implications for neuroinflammation and neurodegeneration in AD.

4.1 Mechanisms of Lipid Droplet Formation in Microglia

Lipid droplets (LDs) are dynamic organelles involved in lipid storage and metabolism, essential for cellular energy balance. In AD, microglial LD accumulation signals disrupted lipid metabolism, contributing to neurodegeneration [12]. LD formation is primarily governed by diacylglycerol acyltransferase (DGAT) and adipose triglyceride lipase (ATGL), which mediate neutral lipid synthesis and hydrolysis.

Recent research shifts focus from amyloid and tau-centric paradigms to include lipid metabolism's role in AD, highlighting its interactions with pathological processes like gamma oscillations and prion-like mechanisms [33]. Dysregulated lipid metabolism, particularly impaired lipid raft formation, is implicated in synaptic dysfunction and memory deficits [13]. The presence of lipid droplet-accumulating microglia (LDAM) in aging brains suggests these organelles may exacerbate inflammatory states and neurodegeneration [12].

Advancements in computational models, such as the Data-driven Inference of Vertex-wise Evolution (DIVE), facilitate exploration of LD accumulation's role in neuroinflammation and neurodegeneration. These models elucidate structural changes linked to altered lipid metabolism in AD, illustrating how impaired lipid raft formation contributes to neurodegeneration, tau phosphorylation, and chronic amyloid beta production [33, 13].

Lifestyle interventions like intermittent fasting and caloric restriction have shown potential neuroprotective effects by modulating lipid metabolism and reducing neuroinflammation, offering promising therapeutic strategies to mitigate AD progression [40]. Understanding microglial lipid droplet formation and its role in AD pathogenesis is crucial for advancing knowledge of this complex disorder and developing effective interventions.

4.2 Lipid Metabolism Alterations in Alzheimer's Disease

Alzheimer's Disease (AD) is marked by amyloid-beta (A) plaques and neurofibrillary tangles, central to its pathophysiology [33]. Recent research highlights lipid metabolism alterations as both a hallmark and a contributing factor to AD progression. Microglial lipid droplet (LD) accumulation indicates disrupted lipid homeostasis in AD brains [27], linked to impaired lipid raft formation essential for synaptic function [13].

To illustrate these complex interactions, Figure 4 presents a hierarchical classification of lipid metabolism alterations in AD, emphasizing key pathologies such as amyloid-beta plaques and neurofibrillary tangles. The figure also highlights lipid droplet accumulation as an indicator of disrupted lipid homeostasis, alongside mechanisms like aberrant amyloid precursor protein (APP) processing. Furthermore, it includes models such as the Conditional Restricted Boltzmann Machine (CRBM) and the Network Aggregation Model, which provide insights into disease progression and protein aggregation dynamics. Therapeutic insights are also discussed, revealing shared mechanisms with conditions like type 2 diabetes mellitus, and the exploration of blood-based metabolic signatures as potential biomarkers for early diagnosis and intervention.

Lipid metabolism dysregulation in AD is intricately tied to A plaques and neurofibrillary tangles formed by hyperphosphorylated tau proteins [33]. Aberrant APP processing leads to toxic A aggregates that disrupt neuronal communication and contribute to synaptic dysfunction. This interplay between lipid metabolism and protein aggregation is further complicated by protein phase coexistence concepts from polymer physics in AD pathogenesis.

Emerging computational models, like the CRBM, predict disease trajectories by modeling lipid metabolism alterations in AD, offering novel insights into disease progression [49]. Models capturing protein aggregation and brain structural connectivity interactions provide insights into protein aggregation dynamics in AD pathogenesis [36].

Lipid metabolism alterations in AD suggest shared mechanisms with conditions like type 2 diabetes mellitus [2], highlighting potential systemic therapeutic interventions targeting metabolic pathways to mitigate AD progression. Exploration of blood-based metabolic signatures advances understanding of AD pathogenesis, identifying metabolites related to amino acids and oxidative stress as potential biomarkers for early diagnosis and intervention [25].

Continued exploration of lipid metabolism alterations in AD is imperative for uncovering innovative therapeutic targets. This ongoing investigation is vital for developing effective interventions to slow AD progression and enhance patient outcomes. As dementia prevalence is projected to rise significantly by 2050, understanding metabolic dysfunctions associated with AD, particularly involving lipid rafts, can inform targeted therapies and lifestyle modifications. Identifying blood-based metabolic signatures presents a promising avenue for early diagnosis and personalized treatment strategies, especially concerning genetic risk factors like APOE alleles [50, 25, 26, 4, 13]. Integrating advanced computational models, neuroimaging techniques, and blood-based biomarkers offers promising avenues for advancing understanding of AD and its underlying pathophysiology, ultimately informing the development of targeted therapeutic strategies.



Figure 4: This figure illustrates the hierarchical classification of lipid metabolism alterations in Alzheimer's Disease (AD), focusing on key pathologies, underlying mechanisms, and potential therapeutic insights. The key pathologies include amyloid-beta plaques and neurofibrillary tangles, with lipid droplet accumulation indicating disrupted lipid homeostasis. Mechanisms and models such as aberrant amyloid precursor protein processing, the Conditional Restricted Boltzmann Machine (CRBM), and the Network Aggregation Model offer insights into disease progression and protein aggregation dynamics. Therapeutic insights highlight shared mechanisms with type 2 diabetes mellitus, the exploration of blood-based metabolic signatures as biomarkers, and the role of lifestyle interventions and genetic factors in AD pathogenesis.

5 Neuroinflammation in Alzheimer's Disease

Advanced Natural Language Processing (NLP) techniques have revolutionized the extraction of sleep-related data from clinical notes of Alzheimer's disease (AD) patients. Traditional methods, often inefficient and reliant on subjective reports, limit research on the sleep-cognition relationship in aging populations. A rule-based NLP algorithm and machine learning models were developed to automate the identification of sleep-related concepts, such as daytime sleepiness and sleep quality, from over 7,000 annotated AD patient datasets. The rule-based NLP algorithm excelled, achieving perfect Positive Predictive Values for certain sleep metrics, thereby enhancing understanding of sleep's impact on AD and enabling broader applications in various medical conditions [17, 51, 52, 16].

Exploring neuroinflammation in AD involves understanding the complex interplay of biological and environmental factors. This exploration is crucial for elucidating neuroinflammation mechanisms and identifying potential therapeutic interventions. The following subsection examines the roles of microglia, the gut-brain axis, and genetic and environmental factors in shaping AD's neuroinflammatory landscape.

5.1 Contribution of Other Factors to Neuroinflammation

Alzheimer's Disease (AD) pathogenesis involves complex factors contributing to neuroinflammation, with microglia playing a central role. In AD, microglia shift from a neuroprotective to a pro-inflammatory phenotype, exacerbating neuronal damage and cognitive decline [27]. This shift is influenced by amyloid-beta (A) plaques and neurofibrillary tangles of hyperphosphorylated tau proteins, central to AD pathology [33].

Recent research emphasizes gut microbiota's role, suggesting microbial metabolites modulate neuroinflammatory responses, contributing to AD pathogenesis [6]. This highlights the potential for a gut-brain axis to influence AD progression, opening therapeutic avenues targeting microbial dysbiosis.

The interaction of genetic, environmental, and metabolic factors is crucial for understanding AD neuroinflammation [2]. Shared pathological pathways between AD and conditions like type 2 diabetes mellitus indicate broader systemic involvement, necessitating a comprehensive approach to AD understanding and treatment [2].

Advancements in computational techniques have enhanced AD neuroinflammation study. Automated feature selection methods, such as random forest algorithms, improve research accuracy by identifying discriminative features in complex datasets [53]. Integrating genetic, imaging, and clinical data through scalable approaches can uncover associations with rare genetic variants, providing deeper insights into AD neuroinflammation's genetic underpinnings.

Recognizing the interplay of factors contributing to AD neuroinflammation, including A plaques, tau protein aggregation, and activated microglia, allows researchers to utilize advanced computational models and imaging techniques to formulate precise therapeutic strategies. These strategies aim to mitigate chronic inflammation's harmful impacts, potentially decelerating this debilitating neurodegenerative disorder's progression, enhancing patient outcomes, and advancing AD pathology understanding [11, 44, 54].

5.2 Mechanisms Exacerbating Neurodegeneration

Neuroinflammation significantly influences neurodegeneration in Alzheimer's Disease (AD) by interacting with amyloid-beta (A) plaques and neurofibrillary tangles of hyperphosphorylated tau proteins. This inflammatory response involves microglia activation, contributing to neuronal damage and cognitive decline. The interplay between neuroinflammation and protein aggregates exacerbates neuronal loss, highlighting the complex relationship between immune responses and neurodegenerative processes in AD [11, 10, 55, 56]. Chronic microglial activation leads to sustained pro-inflammatory cytokine release, initially protective but harmful over time, resulting in neuronal damage and accelerating AD-associated cognitive decline.

Toll-like receptors (TLRs) modulate neuroinflammation, facilitating A plaque clearance or exacerbating neurodegeneration through excessive inflammatory responses [14]. The complex interplay between microglial activation, lipid droplet accumulation, and A plaques and tau protein aggregates formation complicates AD's pathophysiological landscape.

Emerging research suggests AD's potential systemic nature, with shared pathological pathways identified between AD and type 2 diabetes mellitus [2]. This indicates metabolic dysfunctions, including lipid metabolism-related ones, may exacerbate AD neurodegenerative processes. Lipid droplet-accumulating microglia (LDAM) in the aging brain, indicative of a dysfunctional and pro-inflammatory state, underscore lipid metabolism's role in exacerbating AD neurodegeneration [12].

Advancements in computational models and imaging techniques offer new insights into interactions between neuroinflammation, lipid droplet accumulation, and AD neurodegeneration. Automated feature selection methods, such as random forest algorithms, improve research accuracy by identifying discriminative features in complex datasets [53]. Advanced neuroimaging techniques, like the Data-driven Inference of Vertex-wise Evolution (DIVE) model, provide valuable insights into long-term brain pathology patterns and their relationship to AD cognitive decline [38].

Significant strides have been made in identifying immune-related biomarkers for early Alzheimer's disease (AD) diagnosis. Using blood samples and sophisticated computational methods, including machine learning algorithms and mechanistic modeling approaches, researchers explore central nervous system immune cells' interplay with peripheral immune responses. These innovations aim to develop accessible and cost-effective blood-based AD diagnostic methods. Advanced data mining techniques, like the SCARF algorithm, uncover complex combinatorial biomarkers from extensive patient data, revealing potential associations between physiological parameters and dementia [1, 57]. Understanding neuroinflammation's intricate mechanisms exacerbating AD neurodegeneration is essential for developing targeted therapeutic strategies to mitigate disease progression and improve patient outcomes.



(a) Alzheimer's Disease Pathology [58]

(b) Molecular Process of Dimer and Aggregate Formation [59]

Figure 5: Examples of Mechanisms Exacerbating Neurodegeneration

As shown in Figure 5, exploring mechanisms exacerbating neurodegeneration in Alzheimer's disease (AD) necessitates considering neuroinflammation's role. The figures provide valuable visual aids for understanding these processes. The first image, "Alzheimer's Disease Pathology," shows amyloid precursor protein (APP) and its cleavage by -amyloid (A) and -secretase (BACE1) enzymes, leading to amyloid plaques and neurofibrillary tangles (NFTs), hallmark AD pathology features. The second image presents a flowchart of molecular processes involving dimer and aggregate formation and breakdown, emphasizing these interactions' dynamic nature. Together, these visuals underscore AD neurodegenerative mechanisms' complexity, particularly how neuroinflammatory pathways contribute to disease progression by facilitating accumulation and interaction of pathological proteins.

6 Impaired Brain Metabolism in Alzheimer's Disease

6.1 Overview of Brain Metabolism in Alzheimer's Disease

Alzheimer's Disease (AD) is marked by disruptions in brain metabolism, particularly glucose metabolism, crucial for neuronal function due to the brain's high energy requirements. Impaired glucose metabolism correlates with cognitive decline and neurodegeneration, as evidenced by amyloid-beta plaques and neurofibrillary tangles that disrupt brain function [17, 26, 60, 20, 4]. Studies suggest

alternative energy sources like ketone bodies, through dietary interventions such as intermittent fasting, may support neuronal health [40, 61, 50, 62].

Advanced imaging techniques, including diffusion-weighted imaging (DWI) and functional magnetic resonance imaging (fMRI), reveal altered brain network structures in AD, highlighting the impact of metabolic dysfunction on disease progression [37, 63]. Models like the Data-driven Inference of Vertex-wise Evolution (DIVE) and DeepAD enhance understanding of metabolic disruptions in AD by integrating diverse data sources [38, 54].

This is further illustrated in Figure 6, which highlights the primary aspects of brain metabolism in Alzheimer's Disease. The figure focuses on key areas such as metabolic disruptions, advanced imaging techniques, and potential biomarkers for early diagnosis, thereby underscoring the intricate relationship between these factors.

The relationship between brain metabolism and neurodegeneration is further elucidated through models that conceptualize brain tasks as networks, underscoring the importance of metabolic homeostasis for cognitive function [39]. Blood-based metabolic signatures related to amino acids and oxidative stress have emerged as potential biomarkers for early diagnosis in AD [25]. Investigating these metabolic alterations is crucial for developing interventions to maintain cognitive function and improve quality of life for AD patients.



Figure 6: This figure illustrates the primary aspects of brain metabolism in Alzheimer's Disease, focusing on metabolic disruptions, imaging techniques, and biomarkers and models. It highlights key areas such as glucose metabolism, advanced imaging techniques, and potential biomarkers for early diagnosis.

6.2 Glucose Metabolism and Cognitive Impairment

Impaired glucose metabolism is a critical factor in AD-related cognitive decline, linked to amyloid-beta plaques and neurofibrillary tangles that disrupt neuronal function and exacerbate metabolic dysfunction. Glucose hypometabolism often precedes cognitive symptoms by years [17, 26, 60, 20, 4]. Amyloid-beta plaques reduce glucose uptake, leading to energy deficits in affected brain regions [33, 1], while interactions with tau proteins further promote neurodegeneration [33].

Multimodal imaging studies reveal significant disruptions in brain connectivity and metabolic activity associated with cognitive decline [37, 63]. Machine learning techniques, such as the DIVE model, enhance classification of AD using neuroimaging data, providing insights into the progression of metabolic dysfunctions [38]. Blood-based metabolic signatures related to amino acids and oxidative stress underscore the need for innovative approaches integrating genetic, imaging, and clinical data to understand glucose metabolism's impact on cognitive decline [25].

As illustrated in Figure 7, the hierarchical categorization of key aspects related to glucose metabolism and cognitive impairment in Alzheimer's Disease highlights not only impaired glucose metabolism but also the insights gained from imaging and machine learning, as well as the potential benefits of lifestyle interventions. These lifestyle interventions, including intermittent fasting, show promise in influencing neuroprotection and synaptic plasticity, emphasizing the need for further research into their role in AD management [40]. Understanding glucose metabolism's impact on cognitive impairment is vital for developing effective therapeutic strategies to slow disease progression and improve patient outcomes.



Figure 7: This figure illustrates the hierarchical categorization of key aspects related to glucose metabolism and cognitive impairment in Alzheimer's Disease, highlighting impaired glucose metabolism, imaging and machine learning insights, and lifestyle interventions.

6.3 Mechanisms Linking Lipid Droplets and Metabolic Dysfunction

Metabolic dysfunction, particularly in lipid metabolism, is a key factor in AD pathogenesis. Lipid droplets (LDs), which store neutral lipids, are crucial for cellular energy homeostasis. In AD, LD accumulation within microglia indicates disrupted lipid homeostasis, contributing to neuroinflammation and neurodegeneration [12]. Dysregulated lipid metabolism is linked to amyloid-beta plaques and neurofibrillary tangles, central to AD's pathology [33]. Impaired lipid raft formation, essential for synaptic function, exacerbates neurodegeneration [13]. Lipid droplet-accumulating microglia (LDAM) in aging brains suggest a pro-inflammatory state accelerating neurodegeneration [12].

Research connects metabolic dysfunction in AD with conditions like type 2 diabetes, indicating shared pathological pathways for therapeutic targeting [2]. Advances in computational models and imaging techniques elucidate interactions between lipid droplets, neuroinflammation, and neurodegeneration. The Conditional Restricted Boltzmann Machine (CRBM) model predicts disease trajectories by modeling lipid metabolism alterations [49].

Blood-based metabolic signatures have identified metabolites related to amino acids and oxidative stress as potential biomarkers for early diagnosis [25]. Understanding mechanisms linking lipid droplets and metabolic dysfunction is crucial for developing therapeutic strategies to slow AD progression and improve outcomes. Future research should enhance model transparency and integrate diverse data types in machine learning applications for AD, transforming our understanding of the disease and improving patient outcomes [29]. Leveraging advancements in computational models, neuroimaging, and biomarkers can deepen insights into interactions between lipid droplets, metabolic dysfunction, and neurodegeneration in AD, ultimately advancing therapeutic strategies.

7 Interplay Between Lipid Droplets, Neuroinflammation, and Neurodegeneration

7.1 Interactions Between Amyloid, Tau, and Neuroinflammation

Alzheimer's Disease (AD) pathogenesis involves complex interactions among amyloid-beta (A) plaques, tau protein tangles, and neuroinflammatory processes, collectively contributing to neurodegeneration. The prion-like propagation of A and tau proteins intensifies neuroinflammation and neuronal damage, with these proteins promoting each other's aggregation and accelerating disease progression [33]. Computational models illustrate that misfolded tau induces further tau misfolding, resulting in neurofibrillary tangles that impair neuronal function [64]. The interplay between A and tau establishes a chronic neuroinflammatory environment in AD, primarily driven by microglial activation and pro-inflammatory cytokine release, which leads to sustained inflammation and cognitive decline [41]. Recent models have elucidated tau propagation's role in neuroinflammation and disease progression, while low-dimensional representations of neurodegeneration have predicted cognitive impairment, linking brain function to clinical symptoms [65].

This intricate interplay necessitates integrated research approaches acknowledging AD's multifactorial nature. Advanced imaging technologies, such as MRI, combined with computational models like deep learning algorithms, including 3D convolutional neural networks, enhance understanding of AD's biological mechanisms. These methodologies facilitate early diagnosis and identification of pathological brain regions, paving the way for targeted therapeutic strategies aimed at slowing disease progression and improving patient outcomes [66, 46, 67, 68].

7.2 Models and Methodologies for Understanding Interactions

Advancements in computational models have significantly enhanced understanding of the interactions among lipid droplet accumulation, neuroinflammation, and neurodegeneration in AD, crucial for unraveling AD's pathological processes [69]. Microscopic and macroscopic models simulate neurodegenerative processes, providing insights into dynamic relationships between lipid droplets, neuroinflammation, and neurodegeneration [70]. These models capture protein aggregation and clearance complexities, contributing to a comprehensive understanding of AD pathophysiology, essential for developing therapeutic interventions [36].

Integration of genetic, imaging, and clinical data through advanced models like the Conditional Restricted Boltzmann Machine (CRBM) and Disease2Vec enriches understanding of AD interactions, modeling disease trajectories and predicting patient status within AD's progression. These models identify discriminative features, enhancing prognostic performance and offering avenues for early diagnosis and intervention [3]. Optimizing topological feature generation and addressing noise in clinical imaging data are crucial for improving AD diagnosis and prognosis accuracy [71]. Robust deep learning architectures, such as Prototypical Additive Networks (PAN), advance the field by enabling accurate classification of AD patients and studying complex interactions among lipid droplets, neuroinflammation, and neurodegeneration [69].

Future research will refine these methodologies to enhance model transparency and prognostic performance, including advanced noise reduction techniques in clinical imaging datasets through novel neural network architectures integrating patch-based high-resolution 3D convolutional neural networks with global topological features. These adaptations aim to improve diagnostic accuracy and efficiency across clinical imaging tasks [71, 52]. Leveraging these advances, researchers seek to bridge knowledge gaps and develop novel therapeutic strategies targeting interconnected pathways underlying AD pathogenesis, transforming understanding of neurodegenerative disorders and improving patient outcomes.

8 Conclusion

Alzheimer's Disease (AD) presents a formidable challenge to global health, exacerbated by an aging population and characterized by significant cognitive and memory impairments. This survey elucidates the intricate dynamics among microglial dysregulation, lipid droplet accumulation, neuroinflammation, and metabolic dysfunction in AD pathogenesis. Dysregulated microglia, pivotal for modulating neuroinflammation, contribute to chronic inflammatory states that precipitate neuronal damage and advance AD. This dysfunction is closely associated with the pathological accumulation of amyloid-beta plaques and neurofibrillary tangles, hallmark features of the disease.

The accumulation of lipid droplets within microglia is indicative of disrupted lipid metabolism, which intensifies neuroinflammatory responses and accelerates neurodegeneration. The presence of lipid droplet-accumulating microglia in aging brains underscores the connection between lipid dysregulation and heightened inflammatory responses, with impaired plasma membrane lipid raft formation being a critical factor in AD pathology. Understanding the complex interplay between lipid droplets, neuroinflammation, and neurodegeneration remains vital.

Impaired glucose metabolism is another crucial component in AD development, with disruptions in metabolic activity and connectivity contributing to cognitive decline and neuronal loss. Exploring multi-target therapeutic strategies and lifestyle interventions, such as intermittent fasting and caloric restriction, holds promise for slowing disease progression and warrants further investigation.

Future research should emphasize larger cohorts across different AD stages and employ diverse cognitive assessments to validate and expand these findings. The integration of advanced computational models and imaging techniques is crucial for unraveling AD's pathophysiology and crafting targeted

therapeutic strategies. Enhanced clearance mechanisms, as suggested by network aggregation models, offer insights into potential therapies focusing on protein aggregation dynamics. The potential link between AD and type 2 diabetes, with shared causal mechanisms, highlights the need for integrated research approaches.

Emerging research should also explore the therapeutic potential of modulating gut microbiota and its impact on AD pathogenesis, underscoring the importance of addressing systemic factors in disease progression. The adaptation of models like DETree for other diseases and their application to regression tasks using continuous clinical scores could provide valuable insights into disease trajectories. By employing a multi-biomarker approach and integrating machine learning with omics data, researchers can develop patient-specific diagnostic scores, ultimately advancing our understanding of neurodegenerative disorders and enhancing patient outcomes.

References

[1] Balazs Szalkai, Vince K. Grolmusz, Vince I. Grolmusz, and Coalition Against Major Diseases. Identifying combinatorial biomarkers by association rule mining in the camd alzheimer's database, 2013.

[2] Zixin Hu, Rong Jiao, Jiucun Wang, Panpan Wang, Yun Zhu, Jinying Zhao, Phil De Jager, David A Bennett, Li Jin, and Momiao Xiong. Shared causal paths underlying alzheimer's dementia and type 2 diabetes, 2019.

[3] Lu Zhang, Li Wang, Tianming Liu, and Dajiang Zhu. Disease2vec: Representing alzheimer's progression via disease embedding tree, 2022.

[4] Philip Scheltens, Bart De Strooper, Miia Kivipelto, Henne Holstege, Gael Chételat, Charlotte E Teunissen, Jeffrey Cummings, and Wiesje M van der Flier. Alzheimer's disease. *The Lancet*, 397(10284):1577–1590, 2021.

[5] A. Kabbara, H. Eid, EL W. Falou, M. Khalil, F. Wendling, and M. Hassan. Reduced integration and improved segregation of functional brain networks in alzheimer's disease, 2018.

[6] F. Palermo, N. Marrocco, L. Dacomo, E. Grisafi, M. Musella, V. Moresi, A. Sanna, L. Massimi, I. Bukreeva, O. Junemann, I. Viola, M. Eckermann, P. Cloetens, T. Weitkamp, G. Gigli, G. Logroscino, N. Kerlero de Rosbo, C. Balducci, and A. Cedola. Micro and nano 3d investigation of complex gut alterations-dementia interplay, 2024.

[7] Richa Hanamsagar and Staci D Bilbo. Environment matters: microglia function and dysfunction in a changing world. *Current opinion in neurobiology*, 47:146–155, 2017.

[8] Guy C Brown. The endotoxin hypothesis of neurodegeneration. *Journal of neuroinflammation*, 16(1):180, 2019.

[9] Robert P Friedland and Matthew R Chapman. The role of microbial amyloid in neurodegeneration. *PLoS pathogens*, 13(12):e1006654, 2017.

[10] Róisín M McManus and Michael T Heneka. Role of neuroinflammation in neurodegeneration: new insights. *Alzheimer's research & therapy*, 9:1–7, 2017.

[11] Marta Bolós, Juan Ramón Perea, and Jesús Avila. Alzheimer's disease as an inflammatory disease. *Biomolecular concepts*, 8(1):37–43, 2017.

[12] Julia Marschallinger, Tal Iram, Macy Zardeneta, Song E Lee, Benoit Lehallier, Michael S Haney, John V Pluvinage, Vidhu Mathur, Oliver Hahn, David W Morgens, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. *Nature neuroscience*, 23(2):194–208, 2020.

[13] Ari Rappoport. A lipid rafts theory of alzheimer's disease, 2024.

[14] Bernd L Fiebich, Carla Ribeiro Alvares Batista, Soraya Wilke Saliba, Nizar M Yousif, and Antonio Carlos Pinheiro De Oliveira. Role of microglia tlrs in neurodegeneration. *Frontiers in cellular neuroscience*, 12:329, 2018.

[15] Cécile Proust-Lima, Viviane Philipps, and Jean-François Dartigues. A joint model for multiple dynamic processes and clinical endpoints: application to alzheimer's disease, 2019.

[16] Matej Mihelčić, Goran Šimić, Mirjana Babić Leko, Nada Lavrač, Sašo Džeroski, and Tomislav Šmuc. Using redescription mining to relate clinical and biological characteristics of cognitively impaired and alzheimer's disease patients, 2017.

[17] Jason Weller and Andrew Budson. Current understanding of alzheimer's disease diagnosis and treatment. *F1000Research*, 7:F1000–Faculty, 2018.

[18] Ankur Patel, Grishma joshi, and Rupali Ugile. Stem cell therapy for alzheimer's disease, 2016.

[19] Sheng Mai. Mechanisms in neurodegenerative disorders and role of non-pharmacological interventions in improving neurodegeneration and its clinical correlates: A review, 2023.

[20] Zeinab Breijyeh and Rafik Karaman. Comprehensive review on alzheimer's disease: causes and treatment. *Molecules*, 25(24):5789, 2020.

[21] Abdulahad Bayraktar, Tugba Onal-Suzek, Baris Ethem Suzek, and Omur Baysal. Meta-analysis of gene expression in neurodegenerative diseases reveals patterns in gaba synthesis and heat stress pathways, 2019.

[22] Flavio Di Palo and Natalie Parde. Enriching neural models with targeted features for dementia detection, 2019.

[23] Kilian Hett, Vinh-Thong Ta, Jose Vicente Manjon, and Pierrick Coupé. Graph of brain structures grading for early detection of alzheimer's disease, 2018.

[24] Joachim Enengl and Peter Dungel. neverforget - photobiomodulation against alzheimer's disease: A systematic review, 2019.

[25] Francisca A. de Leeuw, Carel F. W. Peeters, Maartje I. Kester, Amy C. Harms, Eduard A. Struys, Thomas Hankemeier, Herman W. T. van Vlijmen, Sven J. van der Lee, Cornelia M. van Duijn, Philip Scheltens, Ayşe Demirkan, Mark A. van de Wiel, Wiesje M. van der Flier, and Charlotte E. Teunissen. Blood-based metabolic signatures in alzheimer's disease, 2017.

[26] Yiming Li and Yuan Luo. Metabolomics of aging and alzheimer's disease: From single-omics to multi-omics, 2022.

[27] Brandon C Farmer, Adeline E Walsh, Jude C Kluemper, and Lance A Johnson. Lipid droplets in neurodegenerative disorders. *Frontiers in neuroscience*, 14:742, 2020.

[28] Paula Desplats, Ashley M. Gutierrez, Marta C. Antonelli, and Martin G. Frasch. Microglial memory of early life stress and inflammation: susceptibility to neurodegeneration in adulthood, 2019.

[29] Zibin Zhao. Towards alzheimer's disease progression assessment: A review of machine learning methods, 2022.

[30] Richard A Armstrong. Risk factors for alzheimer's disease. *Folia neuropathologica*, 57(2):87–105, 2019.

[31] Juan Manuel Fernández Montenegro. Alzheimer's disease diagnosis based on cognitive methods in virtual environments and emotions analysis, 2018.

[32] Shofiul Azam, Md Ezazul Haque, Rengasamy Balakrishnan, In-Su Kim, and Dong-Kug Choi. The ageing brain: molecular and cellular basis of neurodegeneration. *Frontiers in cell and developmental biology*, 9:683459, 2021.

[33] Liyuan Fan, Chengyuan Mao, Xinchao Hu, Shuo Zhang, Zhihua Yang, Zhengwei Hu, Huifang Sun, Yu Fan, Yali Dong, Jing Yang, et al. New insights into the pathogenesis of alzheimer's disease. *Frontiers in neurology*, 10:1312, 2020.

[34] Zhijian Yang, Ilya M. Nasrallah, Haochang Shou, Junhao Wen, Jimit Doshi, Mohamad Habes, Guray Erus, Ahmed Abdulkadir, Susan M. Resnick, David Wolk, and Christos Davatzikos. Disentangling brain heterogeneity via semi-supervised deep-learning and mri: dimensional representations of alzheimer's disease, 2021.

[35] Di Wang, Nicolas Honnorat, Peter T. Fox, Kerstin Ritter, Simon B. Eickhoff, Sudha Seshadri, and Mohamad Habes. Deep neural network heatmaps capture alzheimer's disease patterns reported in a large meta-analysis of neuroimaging studies, 2022.

[36] Georgia S. Brennan and Alain Goriely. A network aggregation model for the dynamics and treatment of neurodegenerative diseases at the brain scale, 2024.

[37] Jeremy Guillon, Mario Chavez, Federico Battiston, Yohan Attal, Valentina La Corte, Michel Thiebaut de Schotten, Bruno Dubois, Denis Schwartz, Olivier Colliot, and Fabrizio De Vico Fallani. Disrupted core-periphery structure of multimodal brain networks in alzheimer's disease, 2018.

[38] Razvan V. Marinescu, Arman Eshaghi, Marco Lorenzi, Alexandra L. Young, Neil P. Oxtoby, Sara Garbarino, Sebastian J. Crutch, and Daniel C. Alexander. Dive: A spatiotemporal progression model of brain pathology in neurodegenerative disorders, 2019.

[39] Oscar Sotolongo-Costa, L. M. Gaggero-Sager, J. T. Becker, F. Maestú, and O. Sotolongo-Grau. A physical model for dementia, 2016.

[40] Eric Mayor. Neurotrophic effects of intermittent fasting, calorie restriction and exercise: A review and annotated bibliography, 2023.

[41] Marco Colonna and Oleg Butovsky. Microglia function in the central nervous system during health and neurodegeneration. *Annual review of immunology*, 35(1):441–468, 2017.

[42] Taeho Jo, Kwangsik Nho, and Andrew J. Saykin. Deep learning in alzheimer's disease: Diagnostic classification and prognostic prediction using neuroimaging data, 2019.

[43] Yi Ren Fung, Ziqiang Guan, Ritesh Kumar, Joie Yeahuay Wu, and Madalina Fiterau. Alzheimer's disease brain mri classification: Challenges and insights, 2019.

[44] Giorgio Dolci, Federica Cruciani, Md Abdur Rahaman, Anees Abrol, Jiayu Chen, Zening Fu, Ilaria Boscolo Galazzo, Gloria Menegaz, and Vince D. Calhoun. An interpretable generative multimodal neuroimaging-genomics framework for decoding alzheimer's disease, 2025.

[45] Michiel Bertsch, Bruno Franchi, Norina Marcello, Maria Carla Tesi, and Andrea Tosin. Alzheimer's disease: a mathematical model for onset and progression, 2016.

[46] Thomas Yu Chow Tam, Litian Liang, Ke Chen, Haohan Wang, and Wei Wu. A quantitative approach for evaluating disease focus and interpretability of deep learning models for alzheimer's disease classification, 2024.

[47] E. G. Lobanova, S. V. Lobanov, K. Triantafilou, W. Langbein, and P. Borri. Quantitative chemical imaging of amyloid-$\beta plaques with raman micro - spectroscopy in human alzheimer's diseased brains$, 2018.

[48] Ehsan Hosseini-Asl, Georgy Gimel'farb, and Ayman El-Baz. Alzheimer's disease diagnostics by a deeply supervised adaptable 3d convolutional network, 2016.

[49] Charles K. Fisher, Aaron M. Smith, Jonathan R. Walsh, and the Coalition Against Major Diseases. Deep learning for comprehensive forecasting of alzheimer's disease progression, 2018.

[50] Helena U. Zacharias, Christoph Kaleta, Francois Cossais, Eva Schaeffer, Henry Berndt, Lena Best, Thomas Dost, Svea Glüsing, Mathieu Groussin, Mathilde Poyet, Sebastian Heinzel, Corinna Bang, Leonard Siebert, Tobias Demetrowitsch, Frank Leypoldt, Rainer Adelung, Thorsten Bartsch, Anja Bosy-Westphal, Karin Schwarz, and Daniela Berg. Microbiome and metabolome insights into the role of the gastrointestinal-brain axis in neurodegenerative diseases: unveiling potential therapeutic targets, 2022.

[51] Alejandro Puente-Castro, Enrique Fernandez-Blanco, Alejandro Pazos, and Cristian R. Munteanu. Automatic assessment of alzheimer's disease diagnosis based on deep learning techniques, 2021.

[52] Sonish Sivarajkumar, Thomas Yu CHow Tam, Haneef Ahamed Mohammad, Samual Viggiano, David Oniani, Shyam Visweswaran, and Yanshan Wang. Extraction of sleep information from clinical notes of patients with alzheimer's disease using natural language processing, 2024.

[53] Saman Sarraf and Ghassem Tofighi. Classification of alzheimer's disease using fmri data and deep learning convolutional neural networks, 2016.

[54] Somaye Hashemifar, Claudia Iriondo, Evan Casey, Mohsen Hejrati, and for Alzheimer's Disease Neuroimaging Initiative. Deepad: A robust deep learning model of alzheimer's disease progression for real-world clinical applications, 2023.

[55] Larisa I Labzin, Michael T Heneka, and Eicke Latz. Innate immunity and neurodegeneration. *Annual review of medicine*, 69(1):437–449, 2018.

[56] Xiaoying Chen, Maria Firulyova, Melissa Manis, Jasmin Herz, Igor Smirnov, Ekaterina Aladyeva, Chanung Wang, Xin Bao, Mary Beth Finn, Hao Hu, et al. Microglia-mediated t cell infiltration drives neurodegeneration in tauopathy. *Nature*, 615(7953):668–677, 2023.

[57] Sophia Krix, Ella Wilczynski, Neus Falgàs, Raquel Sánchez-Valle, Eti Yoles, Uri Nevo, Kuti Baruch, and Holger Fröhlich. Towards early diagnosis of alzheimer's disease: Advances in immune-related blood biomarkers and computational modeling approaches, 2023.

[58] Alfredo Sanabria-Castro, Ileana Alvarado-Echeverría, and Cecilia Monge-Bonilla. Molecular pathogenesis of alzheimer's disease: an update. *Annals of neurosciences*, 24(1):46–54, 2017.

[59] Travis B. Thompson, Georg Meisl, Tuomas Knowles, and Alain Goriely. The role of clearance mechanisms in the kinetics of toxic protein aggregates involved in neurodegenerative diseases, 2020.

[60] Michael A DeTure and Dennis W Dickson. The neuropathological diagnosis of alzheimer's disease. *Molecular neurodegeneration*, 14(1):32, 2019.

[61] Michael Shaughness, Deanna Acs, Fiona Brabazon, Nicole Hockenbury, and Kimberly R Byrnes. Role of insulin in neurotrauma and neurodegeneration: a review. *Frontiers in neuroscience*, 14:547175, 2020.

[62] Cheryl A. Hawkes, Victoria Goss, Elina Zotova, Tual Monfort, Anthony Postle, Sumeet Mahajan, James A. R. Nicoll, Roy O. Weller, and Roxana O. Carare. Impact of maternal high fat on neurovascular unit of adult offspring, 2024.

[63] Mayssa Soussia and Islem Rekik. A review on image- and network-based brain data analysis techniques for alzheimer's disease diagnosis reveals a gap in developing predictive methods for prognosis, 2018.

[64] Veronica Tora, Justin Torok, Michiel Bertsch, and Ashish Raj. A network-level transport model of tau progression in the alzheimer's brain, 2024.

[65] D Jones, Val Lowe, Jonathan Graff-Radford, Hugo Botha, Leland Barnard, D Wiepert, Matthew C Murphy, Melissa Murray, Matthew Senjem, Jeffrey Gunter, et al. A computational model of neurodegeneration in alzheimer's disease. *Nature communications*, 13(1):1643, 2022.

[66] Kuo Yang and Emad A. Mohammed. A review of artificial intelligence technologies for early prediction of alzheimer's disease, 2020.

[67] Adrien Payan and Giovanni Montana. Predicting alzheimer's disease: a neuroimaging study with 3d convolutional neural networks, 2015.

[68] Sarasadat Foroughipoor, Kimia Moradi, and Hamidreza Bolhasani. Alzheimers disease diagnosis by deep learning using mri-based approaches, 2023.

[69] Tom Nuno Wolf, Sebastian Pölsterl, and Christian Wachinger. Don't panic: Prototypical additive neural network for interpretable classification of alzheimer's disease, 2023.

[70] Michiel Bertsch, Bruno Franchi, Maria Carla Tesi, and Andrea Tosin. Microscopic and macroscopic models for the onset and progression of alzheimer's disease, 2017.

[71] Sarah C. Brüningk, Felix Hensel, Catherine R. Jutzeler, and Bastian Rieck. Image analysis for alzheimer's disease prediction: Embracing pathological hallmarks for model architecture design, 2021.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.